The main treatments for bladder cancer depend on the stage and type

Bladder cancer treatment falls into three main categories: surgery, chemotherapy, and radiation. Which one you receive—or whether you receive a combination—depends on how deep the cancer has grown into the bladder wall, whether it has spread beyond the bladder, and your overall health. Early-stage cancers confined to the inner lining of the bladder are often treated with surgery alone. More advanced cancers typically require chemotherapy before or after surgery, and sometimes radiation as well.

Your doctor will discuss the stage of your cancer (determined by imaging and biopsy) and recommend a treatment plan tailored to your situation. The goal is to remove or destroy cancer cells while preserving bladder function when possible, though some patients do require removal of the entire bladder.

Key Takeaways

  • Early-stage bladder cancers confined to the inner lining are often treated with transurethral resection (TURBT), a procedure that removes tumors without removing the bladder.
  • Muscle-invasive cancers that have grown into the bladder wall typically require chemotherapy followed by either radical cystectomy (bladder removal) or radiation combined with chemotherapy.
  • Intravesical therapy—drugs delivered directly into the bladder through a catheter—is used after TURBT to reduce the risk of cancer returning.
  • Advanced cancers that have spread beyond the bladder are usually treated with systemic chemotherapy, immunotherapy, or both.
  • Treatment decisions involve weighing the effectiveness of each option against side effects and impact on quality of life, including urinary function.

Surgery for early-stage bladder cancer

Transurethral resection of the bladder tumor (TURBT) is the standard first step for cancers that have not invaded the muscle layer of the bladder. During this procedure, a cystoscope (a thin tube with a camera and cutting tool) is passed through the urethra into the bladder. The surgeon uses the tool to remove the visible tumor and a margin of surrounding tissue, then sends samples to pathology to confirm the cancer stage.

TURBT is performed under general or spinal anesthesia and usually takes 30 to 90 minutes. Most patients go home the same day or after an overnight stay. You may experience blood in the urine, urinary urgency, and mild pain during urination for a few days afterward. A catheter may be left in place temporarily to help drain the bladder while it heals.

TURBT alone is often sufficient for low-grade, non-muscle-invasive cancers. However, the cancer recurs in the bladder in roughly 50 to 70 percent of patients within five years, which is why follow-up treatment and surveillance are important.

Intravesical therapy to prevent recurrence

After TURBT, many patients receive intravesical therapy—medication delivered directly into the bladder through a catheter. The most common agent is bacillus Calmette-Guérin (BCG), a live attenuated bacterium that stimulates the immune system to attack remaining cancer cells. BCG is instilled into the bladder once a week for six weeks, with the patient holding the liquid inside for about two hours before draining it.

Chemotherapy drugs such as mitomycin C can also be delivered intravesically, particularly for lower-risk cancers or patients who cannot tolerate BCG. Intravesical chemotherapy is typically given as a single dose shortly after TURBT, sometimes followed by additional weekly doses.

BCG is more effective than chemotherapy at preventing recurrence and progression, but it causes more side effects: urinary urgency, frequency, dysuria (painful urination), and occasionally systemic symptoms like fever or flu-like illness. These effects usually resolve within 48 hours of treatment. Maintenance BCG—given periodically over one to three years—further reduces recurrence risk in high-risk patients.

Treatment for muscle-invasive bladder cancer

When cancer has invaded the muscle layer of the bladder wall, surgery alone is not sufficient. The standard approach is radical cystectomy—removal of the entire bladder, prostate (in men), and surrounding lymph nodes. In women, the uterus and ovaries may also be removed. This is major surgery lasting three to four hours, typically followed by a hospital stay of five to seven days.

Before cystectomy, most patients receive neoadjuvant chemotherapy—chemotherapy given before surgery to shrink the tumor and reduce the risk of cancer spreading. The most common regimen is cisplatin-based combination chemotherapy given over several weeks. This approach improves survival compared to surgery alone, though it carries side effects including nausea, fatigue, hearing loss, and kidney or nerve damage.

After the bladder is removed, the surgeon creates a new way for urine to leave the body. The most common option is an ileal conduit, in which a segment of small intestine is used to create a passage from the ureters to an opening (stoma) on the abdomen. Urine drains continuously into an external pouch worn on the skin. Alternatively, a continent reservoir (also called a neobladder) can be constructed from intestinal tissue, allowing urine to be stored internally and emptied by catheterization or through a valve-controlled stoma.

Radiation and chemotherapy as alternatives to surgery

Some patients with muscle-invasive cancer are not candidates for surgery due to age, other medical conditions, or personal preference. For these patients, trimodal therapy combines maximal TURBT, external beam radiation therapy, and concurrent chemotherapy. Radiation is delivered over five to seven weeks in daily treatments, while chemotherapy (usually cisplatin) is given weekly during the same period.

Trimodal therapy preserves the bladder and avoids major surgery, but it requires careful patient selection. Patients must have had a complete TURBT with no residual tumor visible, adequate kidney function to tolerate chemotherapy, and the ability to tolerate radiation side effects. Success rates are lower than surgery, and some patients eventually require cystectomy if the cancer recurs or persists.

Radiation can cause acute side effects including urinary frequency, dysuria, diarrhea, and fatigue during treatment. Long-term effects may include chronic urinary symptoms, bowel dysfunction, and rarely, secondary cancers in the radiation field years later.

Treatment for advanced and metastatic bladder cancer

When bladder cancer has spread to distant organs (metastatic disease) or involves the pelvic lymph nodes, systemic treatment is necessary. Chemotherapy is the first-line treatment, typically using a cisplatin-based combination regimen such as gemcitabine plus cisplatin. Treatment is given in cycles over several months, with the goal of shrinking tumors and extending survival.

Immunotherapy drugs called checkpoint inhibitors have become increasingly important in recent years. These medications—including atezolizumab, durvalumab, nivolumab, and pembrolizumab—work by removing the brakes cancer cells place on the immune system, allowing the body's own defenses to attack the tumor. Immunotherapy may be used alone or combined with chemotherapy, depending on the patient's fitness and prior treatment history.

For patients who cannot tolerate cisplatin-based chemotherapy due to kidney disease or hearing loss, carboplatin-based regimens or immunotherapy alone may be used instead. Treatment decisions balance the potential for tumor response against side effects and impact on quality of life.

Managing side effects and recovery

Each treatment modality carries distinct side effects. Surgery recovery involves pain at the incision site, temporary bowel dysfunction, and adjustment to a new urinary system if the bladder was removed. Most patients return to normal activities within four to six weeks, though full recovery takes longer.

Chemotherapy side effects depend on the drug and dose but commonly include nausea, vomiting, fatigue, hair loss, and increased infection risk. Blood counts are monitored closely, and supportive medications are given to manage symptoms. Most side effects resolve after treatment ends, though some—such as hearing loss or nerve damage from cisplatin—may be permanent.

Radiation side effects peak during and shortly after treatment but often improve within weeks to months. Chronic side effects are less common but can include persistent urinary or bowel symptoms. Your medical team will discuss strategies to minimize side effects and monitor for long-term complications.

Follow-up care and surveillance

After treatment, regular follow-up is essential because bladder cancer can recur in the remaining bladder tissue or in other parts of the urinary tract. Patients who underwent TURBT have cystoscopy every three months for the first two years, then less frequently if no recurrence is detected. Urine cytology (microscopic examination of urine cells) is also performed regularly.

Patients who had their bladder removed still require surveillance for cancer in the upper urinary tract (ureters and kidneys). This typically involves imaging such as CT scans or ultrasound at regular intervals.

Your oncologist will also monitor for late effects of treatment, including kidney function after chemotherapy, hearing changes, and secondary cancers. Lifestyle factors such as smoking cessation are strongly encouraged, as smoking increases the risk of recurrence and new cancers in the urinary tract.

Frequently Asked Questions

Can bladder cancer be cured?

Early-stage bladder cancers confined to the inner lining have high cure rates, particularly with TURBT and intravesical therapy. Muscle-invasive cancers treated with radical cystectomy and chemotherapy also have good long-term survival in many patients. Advanced cancers are more difficult to cure but may respond to chemotherapy or immunotherapy, extending survival significantly.

What happens to urinary function after bladder removal?

An ileal conduit requires wearing an external pouch that collects urine continuously throughout the day. A continent reservoir allows you to empty urine by self-catheterization several times daily or through a valve-controlled opening. Both options require adjustment and learning, but most patients adapt well and return to normal activities including work and exercise.

Is chemotherapy always necessary for muscle-invasive cancer?

Neoadjuvant chemotherapy before surgery improves survival outcomes and is recommended for most patients with muscle-invasive bladder cancer who can tolerate it. However, patients with severe kidney disease, hearing loss, or other contraindications may proceed to surgery alone. Your doctor will assess whether chemotherapy is safe and appropriate for your situation.

How long does bladder cancer treatment take?

TURBT is a single procedure. Intravesical BCG typically involves six weekly treatments, then maintenance therapy over months to years. Neoadjuvant chemotherapy takes four to six weeks. Radical cystectomy is one surgery followed by recovery. Radiation therapy is given daily for five to seven weeks. The total timeline depends on which treatments you receive and how your cancer responds.

Can I choose not to have my bladder removed?

For muscle-invasive cancer, trimodal therapy (TURBT, radiation, and chemotherapy) is an alternative to cystectomy that preserves the bladder. However, it requires careful patient selection and close follow-up, and some patients eventually need cystectomy if cancer recurs. Discuss the pros and cons of each option with your oncologist and urologist to make an informed decision.